Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 36,260 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 36,260 shares of Kiniksa Pharmaceuticals International stock in a transaction on Friday, October 30th. The shares were sold at an average price of $94.43, for a total transaction of $3,424,031.80. Following the completion of the sale, the chief accounting officer owned 12,697 shares of the company’s stock, valued at $1,198,977.71. This represents a 74.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 2.7%

Kiniksa Pharmaceuticals International stock opened at $93.29 on Wednesday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $37.02 and a 12-month high of $98.48. The firm’s fifty day moving average is $79.67 and its 200 day moving average is $60.56. The company has a market capitalization of $7.28 billion, a PE ratio of 71.76 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KNSA. Bank of America Corp DE lifted its stake in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after buying an additional 506,576 shares in the last quarter. Rubric Capital Management LP grew its holdings in shares of Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after buying an additional 421,347 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Kiniksa Pharmaceuticals International by 213.5% during the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock worth $23,197,000 after acquiring an additional 327,595 shares in the last quarter. Spruce Street Capital LP increased its position in shares of Kiniksa Pharmaceuticals International by 75.0% during the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after acquiring an additional 326,081 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its position in shares of Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after acquiring an additional 251,578 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Ratings Changes

KNSA has been the subject of a number of research analyst reports. Canaccord Genuity Group boosted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, October 28th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. The Goldman Sachs Group raised their price objective on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Finally, Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.